Published in J Virol on October 30, 2013
Advances in norovirus biology. Cell Host Microbe (2014) 1.45
Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med (2015) 1.09
The state of norovirus vaccines. Clin Infect Dis (2014) 1.05
Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol (2016) 1.01
Virus Genotype Distribution and Virus Burden in Children and Adults Hospitalized for Norovirus Gastroenteritis, 2012-2014, Hong Kong. Sci Rep (2015) 0.97
Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope. J Virol (2014) 0.88
Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol (2014) 0.84
Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses. J Virol (2014) 0.83
Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies. Clin Vaccine Immunol (2014) 0.81
Serum Immunoglobulin A Cross-Strain Blockade of Human Noroviruses. Open Forum Infect Dis (2015) 0.80
Recent advances in understanding norovirus pathogenesis. J Med Virol (2016) 0.77
Recombinant GII.P16-GII.2 Norovirus, Taiwan, 2016. Emerg Infect Dis (2017) 0.75
Phylogenetic Analyses Suggest that Factors Other Than the Capsid Protein Play a Role in the Epidemic Potential of GII.2 Norovirus. mSphere (2017) 0.75
Food-related illness and death in the United States. Emerg Infect Dis (1999) 39.22
Norovirus classification and proposed strain nomenclature. Virology (2005) 7.69
Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis (2008) 7.48
Human susceptibility and resistance to Norwalk virus infection. Nat Med (2003) 7.07
X-ray crystallographic structure of the Norwalk virus capsid. Science (1999) 6.58
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med (2008) 4.57
Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology (2002) 4.13
Coexistence of multiple genotypes, including newly identified genotypes, in outbreaks of gastroenteritis due to Norovirus in Japan. J Clin Microbiol (2004) 3.85
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol (2005) 3.74
Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol (2007) 3.71
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Norwalk virus open reading frame 3 encodes a minor structural protein. J Virol (2000) 2.96
Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep (2011) 2.71
Cellular and humoral immunity following Snow Mountain virus challenge. J Virol (2005) 2.59
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci U S A (2008) 2.54
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Norovirus activity--United States, 2006-2007. MMWR Morb Mortal Wkly Rep (2007) 2.12
X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc Natl Acad Sci U S A (2006) 2.09
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog (2010) 2.02
Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev (2008) 1.96
Organization and expression of calicivirus genes. J Infect Dis (2000) 1.94
Genetic and antigenic diversity among noroviruses. J Gen Virol (2006) 1.91
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine (2006) 1.74
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Deaths from norovirus among the elderly, England and Wales. Emerg Infect Dis (2008) 1.65
Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J Virol (2002) 1.60
Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol (2011) 1.53
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis (2013) 1.47
Genetic analysis of noroviruses associated with fatalities in healthcare facilities. Arch Virol (2006) 1.46
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol (2002) 1.36
Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol (2012) 1.36
Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol (2011) 1.29
Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin Infect Dis (2010) 1.25
Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle. J Virol (2012) 1.21
A single-amino-acid substitution in the P2 domain of VP1 of murine norovirus is sufficient for escape from antibody neutralization. J Virol (2007) 1.20
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol (2009) 1.17
Chronic diarrhea associated with persistent norovirus excretion in patients with chronic lymphocytic leukemia: report of two cases. BMC Infect Dis (2011) 1.11
Noroviruses: the perfect human pathogens? J Infect Dis (2012) 1.09
Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens. J Appl Microbiol (2010) 1.07
Structural basis for norovirus inhibition and fucose mimicry by citrate. J Virol (2011) 1.05
Genetic analysis of the capsid gene of genotype GII.2 noroviruses. J Virol (2008) 1.02
Identification of a Broadly Cross-Reactive Epitope in the Inner Shell of the Norovirus Capsid. PLoS One (2013) 0.92
Diagnosis of norwalk virus infection by indirect enzyme immunoassay detection of salivary antibodies to recombinant norwalk virus antigen. Clin Diagn Lab Immunol (2004) 0.91
A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance. Viral Immunol (1995) 0.90
A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. Clin Infect Dis (2013) 0.77
[Chronic norovirus infection in an immunocompromised patient]. Ned Tijdschr Geneeskd (2010) 0.76
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol (2013) 4.98
Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med (2008) 4.57
Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol (2002) 4.29
Norwalk virus: how infectious is it? J Med Virol (2008) 3.93
Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res (2011) 3.25
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog (2007) 2.71
Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol (2009) 2.60
Cellular and humoral immunity following Snow Mountain virus challenge. J Virol (2005) 2.59
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol (2005) 2.22
Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol (2007) 2.18
Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A (2014) 2.17
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol (2005) 2.05
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A (2008) 1.97
Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev (2008) 1.96
A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol (2013) 1.94
Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol (2002) 1.85
Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. J Virol (2004) 1.80
Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. MBio (2010) 1.79
Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med (2006) 1.78
Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol (2007) 1.75
Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol (2012) 1.75
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine (2006) 1.74
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2013) 1.73
The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication. J Virol (2005) 1.71
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Antibody is critical for the clearance of murine norovirus infection. J Virol (2008) 1.69
Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol (2013) 1.68
Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog (2010) 1.67
Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J Virol (2002) 1.60
Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol (2009) 1.58
Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog (2010) 1.56
Single-amino-acid substitutions in open reading frame (ORF) 1b-nsp14 and ORF 2a proteins of the coronavirus mouse hepatitis virus are attenuating in mice. J Virol (2005) 1.54
Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol (2011) 1.53
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis (2013) 1.47
MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog (2008) 1.47
Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. PLoS Pathog (2013) 1.43
Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio (2013) 1.41
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Norovirus immunity and the great escape. PLoS Pathog (2012) 1.40
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol (2002) 1.36
Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol (2012) 1.36
Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice. G3 (Bethesda) (2012) 1.35
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol (2012) 1.33
Cleavage between replicase proteins p28 and p65 of mouse hepatitis virus is not required for virus replication. J Virol (2004) 1.32
SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog (2010) 1.32
Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol (2011) 1.29
A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med (2012) 1.26
Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol (2011) 1.26
SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Virus Res (2007) 1.24
Systematic assembly of a full-length infectious clone of human coronavirus NL63. J Virol (2008) 1.23
Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis (2013) 1.23
Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol (2005) 1.23
Processing of open reading frame 1a replicase proteins nsp7 to nsp10 in murine hepatitis virus strain A59 replication. J Virol (2007) 1.22
Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome. Proc Natl Acad Sci U S A (2006) 1.22
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol (2011) 1.18
Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol (2011) 1.18
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol (2009) 1.17